

## SUPPLEMENTARY MATERIALS

<b>Table S1. The association of cardiac biomarkers with cardiovascular and all-cause mortality, excluding participants with hyperlipidemia and current smoking.</b>				
	<b>Cardiovascular Mortality</b>		<b>All-Cause Mortality</b>	
	<b>HR (95% CI)</b>	<b><i>p</i></b>	<b>HR (95% CI)</b>	<b><i>p</i></b>
No. of events	43		185	
<b>hsTnT</b>	4.84 (1.26, 18.46)	0.02	1.64 (1.28, 2.09)	0.0002
<b>hsTnI (Abbott)</b>	2.04 (1.41, 2.96)	0.0004	1.39 (1.14, 1.68)	0.002
<b>hsTnI (Ortho)</b>	1.52 (1.21, 1.92)	0.0007	1.00 (0.35, 2.85)	1.00
<b>hsTnI (Siemens)</b>	1.31 (0.84, 2.04)	0.22	1.20 (1.01, 1.44)	0.04
<b>NT-proBNP</b>	2.25 (1.16, 4.33)	0.02	1.23 (1.09, 1.39)	0.002
Modes adjusted for age, sex, race or ethnicity, insurance, former smoking, survey year, food insecurity, BMI, hemoglobin A1c, total cholesterol, systolic blood pressure, physical activity, use of ACEi/ARB, use of statin, eGFR				

<b>Table S2. The association of cardiac biomarkers with all-cause mortality among adults without subclinical CVD.</b>				
	<b>Without Subclinical CVD</b>		<b>With Subclinical CVD</b>	
	<b>HR (95% CI)</b>	<b><i>p</i></b>	<b>HR (95% CI)</b>	<b><i>p</i></b>
No. of events	303		138	
<b>hsTnT</b>				
Model 1	1.26 (0.93, 1.71)	0.13	1.39 (1.03, 1.86)	0.03
Model 2	1.17 (0.87, 1.58)	0.29	1.45 (1.05, 1.99)	0.02
Model 3	1.20 (0.88, 1.64)	0.25	1.47 (1.07, 2.02)	0.02
<b>hsTnI (Abbott)</b>				
Model 1	1.10 (0.89, 1.37)	0.37	1.70 (1.24, 2.32)	0.001
Model 2	1.08 (0.86, 1.35)	0.52	1.55 (1.12, 2.14)	0.009
Model 3	1.08 (0.86, 1.35)	0.50	1.55 (1.12, 2.14)	0.009
<b>hsTnI (Ortho)</b>				
Model 1	1.13 (0.97, 1.32)	0.11	1.84 (1.43, 2.37)	<0.0001
Model 2	1.13 (0.94, 1.37)	0.19	1.68 (1.30, 2.17)	0.0002
Model 3	1.13 (0.94, 1.36)	0.19	1.68 (1.30, 2.17)	0.0002
<b>hsTnI (Siemens)</b>				
Model 1	1.06 (0.92, 1.23)	0.42	1.22 (0.95, 1.56)	0.11
Model 2	1.05 (0.90, 1.21)	0.55	1.12 (0.87, 1.44)	0.37
Model 3	1.05 (0.90, 1.20)	0.54	1.12 (0.87, 1.44)	0.37
<b>NT-proBNP</b>				
Model 1	1.16 (1.01, 1.33)	0.04	1.34 (1.12, 1.61)	0.002
Model 2	1.13 (0.98, 1.30)	0.08	1.31 (1.06, 1.66)	0.03
Model 3	1.14 (0.99, 1.31)	0.08	1.31 (1.03, 1.67)	0.03

Model 1: adjusted for age, sex, race or ethnicity, insurance, smoking, survey year, food insecurity.  
 Model 2: adjusted for Model 2 + BMI, hemoglobin A1c, total cholesterol, systolic blood pressure, physical activity, use of ACEi/ARB, use of statin.  
 Model 3: adjusted for Model 3 + eGFR

<b>Table S3. The association of subclinical CVD with cardiovascular and all-cause mortality.</b>				
	<b>Cardiovascular Mortality</b>		<b>All-Cause Mortality</b>	
	<b>HR (95% CI)</b>	<b>p</b>	<b>HR (95% CI)</b>	<b>p</b>
No. of events	83		441	
<b>Subclinical CVD defined by hs-cTnT and NT-proBNP <sup>a</sup></b>				
Crude	6.75 (3.58, 12.73)	<0.0001	4.23 (2.37, 5.49)	<0.0001
Model 1	2.15 (1.03, 4.51)	0.04	1.87 (1.33, 1.62)	0.0006
Model 2	2.00 (0.82, 4.88)	0.13	1.62 (1.09, 2.42)	0.02
Model 3	1.97 (0.78, 4.97)	0.15	1.62 (1.08, 2.42)	0.02
<b>Subclinical CVD defined by hs-cTnI (Abbott) <sup>b</sup></b>				
Crude	3.00 (0.36, 24.17)	0.30	2.57 (1.08, 6.12)	0.03
Model 1	2.37 (0.36, 15.76)	0.36	2.24 (1.17, 4.27)	0.02
Model 2	2.29 (0.27, 19.39)	0.44	1.81 (0.89, 3.69)	0.10
Model 3	2.27 (0.26, 19.70)	0.45	1.81 (0.88, 3.69)	0.10
<p>Model 1: adjusted for age, sex, race or ethnicity, insurance, smoking status, survey year, food insecurity.            Model 2: adjusted for Model 2 + BMI, hemoglobin A1c, total cholesterol, systolic blood pressure, physical activity, use of ACEi/ARB, use of statin.            Model 3: adjusted for Model 3 + eGFR</p> <p><sup>a</sup> Subclinical CVD defined by hs-cTnT ≥22 ng/L among men or hs-cTnT ≥14 ng/L among women or NT-proBNP &gt;125 pg/mL.  <sup>b</sup> Subclinical CVD defined by hs-cTnI (Abbott) ≥12 ng/L among men and ≥10 ng/L among women.</p>				